Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life, today and tomorrow.

Evonik Vancouver Laboratories has been a market CDMO leader for lipid nanoparticle (LNP)-/liposome-based formulations for almost 30 years with an unparalleled track record in early-stage development, scale-up, and production of lipid-based formulations for gene-based therapies and advanced nanomedicines. As a specialist CDMO for lipid nanoparticles with a broad base of pharmaceutical and biotech clients across the world, Evonik Vancouver Laboratories has accumulated extensive expertise across virtually all classes of pharmaceuticals. Hundreds of LNP-based formulations have been developed to-date, including oncology, vaccines, nucleic acids (mRNA, DNA, siRNA), ligand-targeted formulations, and imaging contrast agents. Evonik Vancouver Laboratories leads the CDMO market for LNPs to address emerging areas of market need including drug combinations, immunotherapies, and individualized treatments. In addition, Evonik designs and manufactures their LIPEX™ line of extruders, which are designed to enable small-scale to commercial scale manufacturing of specific liposomal drug products.